As in MPN, HSP90 inhibition in cHL and multiple myeloma (MM) leads to loss of STAT3 and 5 tyrosine phosphorylation due to JAK1,3 and TYK2 down-regulation [86,87]. This evidence concerns the gene HSP90AB1 and myeloproliferative disorder.